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Introduction
Thrombospondin 1 (TSP-1) was initially discovered in platelets as 
a thrombin-sensitive protein
1) and is a matricellular protein that re-
gulates cell-cell and cell-matrix interactions.
2)3) Functional studies in 
TSP-1
-/- mice have shown that TSP-1 inhibits angiogenesis,
4) promo-
tes the healing of excision wounds,
5) and limits inflammatory respon-
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study has investigated the role of TSP-1 in human atherosclerosis. This study investigated the relationship among plasma TSP-1 concentra-
tion, DM, and coronary artery disease (CAD).
Subjects and Methods: The study involved 374 consecutive subjects with suspected CAD, who had undergone coronary angiography to 
evaluate effort angina. Patients were divided into four groups as follows: DM(-) and CAD(-), DM(-) and CAD(+), DM(+) and CAD(-), and DM 
(+) and CAD(+).
Results: We found that plasma TSP-1 levels were higher in patients with DM(+) and CAD(+) (n=103) than those in other patients (n= 
271) (p<0.01). A multivariate analysis showed that male gender {odds ratio (OR), 2.728; 95% confidence interval (CI), 1.035-7.187}, high 
density lipoprotein-cholesterol (OR, 0.925; 95% CI, 0.874-0.980), glycated hemoglobin (OR, 1.373; 95% CI, 1.037-1.817), and plasma TSP-1 
(OR, 1.004; 95% CI, 1.000-1.008) levels were independently associated with the presence of CAD in patients with DM.
Conclusion: Plasma TSP-1 levels were higher in patients with DM(+) and CAD(+) than those in other patients, and plasma TSP-1 levels 
were independently associated with the presence of CAD in patients with DM. These findings show a possible link between human plasma 
TSP-1 concentration and CAD in patients with DM. (Korean Circ J 2012;42:100-106)
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ses and fibrotic remodeling after myocardial infarction.
6)
TSP-1 also plays a role in platelet aggregation and thrombus ad-
hesion to injured blood vessels and limits nitric oxide-mediated va-
sodilatation and tissue perfusion in experimental models of isch-
emic injury.
7)
Thrombospondin-1 may represent a link between diabetes melli-
tus (DM) and vascular complications.
8)9) High levels of glucose in-
crease TSP-1 expression in renal mesangial cells.
10) TSP-1 promotes 
the pathological events associated with diabetic nephropathy such 
as mesangial cell proliferation and increased extracellular matrix 
production by mesangial cells.
10-13) A peptide blocking the activation 
of transforming growth factor-β by TSP-1 prevents the progression 
of cardiac fibrosis and improves cardiac function in a rat model, sug-
gesting that TSP-1 plays an important role in the development of di-
abetic cardiomyopathy.
14) 
However, the precise role of TSP-1 in human atherosclerosis re-
mains unknown. Therefore, the present clinical study was conduct-
ed to examine the association between TSP-1, coronary artery dis-
ease (CAD), and DM.101 Kyu-Young Choi, et al.
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Subjects and Methods
Study patients
The study involved 374 consecutive subjects (206 men and 168 
women) with suspected CAD from November 2008 to October 2009. 
Patients had undergone coronary angiography (CAG) to evaluate 
angina. The exclusion criteria included acute coronary syndrome, a 
serum creatinine level ≥2.0 mg/dL, and type 1 DM. This study was 
approved by our institutional review board. Each participant provid-
ed written informed consent prior to procedures being performed, 
and potential risks were fully explained.
Patients were considered to have DM if their fasting plasma glu-
cose concentration was ≥126 mg/dL, or their two casual plasma 
glucose concentration was ≥200 mg/dL.
15) Systemic hypertension 
was defined as a systolic blood pressure ≥140 mm Hg or a diastolic 
pressure ≥90 mm Hg.
16) Smokers were defined as those who were 
currently smokers or who had a recent history of smoking (i.e., with-
in the past 1 year). A family history of premature CAD was defined 
as CAD in a male first-degree relative <55 years old and a female 
first-degree relative <65 years old. Body mass index (BMI) was cal-
culated using weight (kilograms) divided by the square of the height 
(meters).
Coronary angiography
Coronary angiography was performed with fasted patients using 
the Judkins technique. Stenosis severity was determined by visual 
estimation in two orthogonal views. Angiographic films were inter-
preted by angiographers without knowledge of patient laboratory 
data. Significant coronary stenosis was defined as a stenosis >50% 
in the left main trunk or >70% in the other major epicardial coro-
nary arteries. Patients with CAD were defined as patients with at 
least one significant coronary stenosis. 
The angiographic characteristics of the coronary atherosclerotic 
lesions were defined using Gensini’s score.
17) In this scoring system, 
a greater reduction in the luminal diameter receives a high score and 
a proximal lesion in the left anterior descending or the left circum-
flex artery is assigned a higher score than that of a distal lesion.
 
Laboratory analysis
Blood was sampled on admission to measure blood chemistry. For 
lipid profiles, patients fasted overnight and blood samples were ob-
tained by venipuncture. Total cholesterol (TC), triglyceride (TG), high 
density lipoprotein-cholesterol (HDL-C), low density lipoprotein-
cholesterol, and high sensitive C-reactive protein (hs-CRP) concen-
trations were determined using standard biochemical procedures 
on a Toshiba automated clinical chemistry analyzer (Toshiba, Tokyo, 
Table 1. Patient baseline characteristics
DM(-)CAD(-) (n=108) DM(-)CAD(+) (n=117) DM(+)CAD(-) (n=46) DM(+)CAD(+) (n=103) p
Age (years) 063.0±11.7 67.0±9.8 64.1±9.1 65.8±9.7 0.026
Male (%) 46 67 35 60 <0.001
Hypertension (%) 45 50 61 65 0.018
Smoking (%) 39 44 24 36 0.104
Family history (%) 06 20 7 10 0.004
BMI (kg/m
2) 25.1±3.8 24.2±3.3 26.8±3.4 25.5±3.1 <0.001
Serum Cr (mg/dL) 00.95±0.22 1.07±0.3 0.98±0.27 1.05±0.32 0.008
Lipid profile
TC (mg/dL) 175.5±37.3 170.9±38.7 184.8±51.0 168.8±43.1 0.140
TG (mg/dL) 123.7±61.8 137.8±74.8 171.2±77.9 146.7±76.0 0.002
HDL-C (mg/dL) 045.7±11.4 41.7±10.9 46.4±11.5 39.5±9.0 <0.001
LDL-C (mg/dL) 105.1±30.4 104.8±33.2 100.1±40.3 99.9±42.4 0.646
Uric acid (mg/dL) 05.39±1.60 5.58±1.72 5.07±1.69 5.69±1.94 0.210
hs-CRP (mg/L) 0.50±0.86 0.54±0.87 0.58±0.81 1.04±1.66 0.003
HbA1c (%) 7.53±1.34 8.03±1.86 0.103
No. of Involv. V. 1.63±0.71 1.82±0.78 0.069
Gensini’s score 39.1±34.8 47.0±44.0 0.141
TSP-1 (ng/mL)  518.0±126.8 513.1±128.4 532.0±123.8 579.0±106.1 <0.001
Values are mean±SD. DM(-)CAD(-): patients without DM or CAD, DM(-)CAD(+): patients without DM but with CAD, DM(+)CAD(-): patients with DM but 
without CAD, DM(+)CAD(+): patients with DM and CAD, DM: diabetes mellitus, CAD: coronary artery disease, BMI: body mass index, Serum Cr: serum cre-
atinine, TC: total cholesterol, TG: triglyceride, HDL-C: high density lipoprotein-cholesterol, LDL-C: low density lipoprotein-cholesterol, hs-CRP: high sensitiv-
ity C-reactive protein, HbA1c: glycated hemoglobin level, No. of Involv. V.: number of involved vessels, TSP-1: plasma thrombospondin-1102  Thrombospodin-1 and Coronary Artery Disease
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Japan). The glycated hemoglobin (HbA1c) level indicates the mean 
blood glucose level during the previous 2 to 3 months. HbA1c con-
centrations were measured using a commercially available glyco-
hemoglobin analyzer (Tosho, Tokyo, Japan).
After an overnight fast, blood samples for TSP-1 were drawn at 
the time of CAG, before administration of contrast agent or medi-
cations. Samples were centrifuged to obtain plasma, and the plas-
ma was immediately stored at -70°C for subsequent analysis. Plas-
ma TSP-1 concentration was assessed using a TSP-1 ELISA kit (R&D 
Systems, Minneapolis, MN, USA) that had a minimum detection level 
of 0.355 ng/mL.
 
Statistical analysis
Categorical variable data are expressed as numbers and percent-
ages of patients. Continuous variable data are expressed as mean± 
SD. A one-way analysis of variance was used to compare the vari-
ables shown in Table 1 and Fig. 1. Post hoc comparisons between 
different groups were conducted with Scheffe’s multiple compari-
son procedures. Chi-square tests were used for categorical variables. 
Pearson’s correlation coefficient analysis was used to assess the 
association between measured parameters. Multivariate logistic re-
gression analysis was used to identify CAD predictors. Univariate 
variables with a p<0.20 were entered into multivariate logistic mod-
els. Multivariate adjusted odds ratios (ORs) are shown with 95% 
confidence intervals (CIs). Differences were considered significant 
at p<0.05.
Results
Baseline patient characteristics
The clinical characteristics of patients in each group are shown in 
Table 1. The four groups were not similar in terms of age, gender ra-
tio, hypertension, family history of CAD, BMI, serum creatinine, TG, 
HDL-C, hsCRP, or TSP-1 levels. Patients with CAD were older and had 
higher serum creatinine levels compared to patients without CAD, 
regardless of DM. Patients with DM and without CAD {DM(+)CAD 
(-) patients} had the highest BMI and TG levels. Patients without 
CAD had higher HDL-C levels compared to those in patients with 
CAD, regardless of DM. HsCRP was highest in patients with DM and 
CAD {DM(+)CAD(+) patients}. The incidences of male gender and a 
family history of CAD were highest in patients without DM and 
with CAD {DM(-)CAD(+)}, and the incidence of hypertension was 
higher in patients with DM than that in patients without DM. The 
four groups were similar in terms of smoking rate, TC, LDL-C, and uric 
acid. No statistical difference was observed between HbA1c level of 
DM(+)CAD(+) patients and that of DM(+)CAD(-) patients. When we 
divided patients with CAD based on DM, Gensini’s score, and the 
number of involved vessels, no significant difference was observed 
between DM(+)CAD(+) patients and DM(-)CAD(+) patients.
Plasma thrombospondin-1 levels according to diabetes 
mellitus and coronary artery disease
Patients were divided into four groups to analyze plasma TSP-1 
Fig. 1. Comparison of plasma thrombospondin-1 (TSP-1) levels. A: patients were divided into four groups to compare plasma TSP-1 levels. Statistical anal-
ysis showed that TSP-1 levels were highest in the DM(+)CAD(+) group. B: when patients were divided into two groups according to the presence of DM, 
plasma levels of TSP-1 were higher in the DM group than those in the non-DM group (577.9±104.5 ng/mL vs. 519.3±123.5 ng/mL, p<0.001). C: when pa-
tients were divided into two groups according to CAD, plasma levels of TSP-1 were not significantly different between the non-CAD and CAD groups 
(532.4±117.0 ng/mL vs. 552.7±120.2 ng/mL, p=0.091). DM(-)CAD(-): patients without DM and without CAD, DM(-)CAD(+): patients without DM and with 
CAD, DM(+)CAD(-): patients with DM but without CAD, DM(+)CAD(+): patients with DM and CAD, TSP-1: thrombospodin-1, DM: diabetes mellitus, CAD: 
coronary artery disease.
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levels. We found that the plasma TSP-1 concentration was higher in 
DM(+)CAD(+) patients compared to that in patients without DM 
and without CAD {DM(-)CAD(-) patients}, DM(-)CAD(+) patients, 
and DM(+)CAD(-) patients (p<0.01) (Fig. 1A). When patients were 
divided into two groups according to DM, plasma TSP-1 levels were 
higher in patients with DM than those in patients without DM 
(564.5±113.5 ng/mL vs. 515.5±127.4 ng/mL, p<0.001) (Fig. 1B). When 
patients were divided into two groups based on the development 
of CAD, plasma levels of TSP-1 were not significantly different be-
tween the non-CAD and CAD group (Fig. 1C). 
Baseline patient medications
Patient medications in each group are shown in Table 2. The four 
groups were not similar in angiotensin converting enzyme inhibi-
tor/angiotensin receptor blocker (ACEi/ARB) or β-blocker use. The 
DM group had a higher rate of ACEi/ARB use than that in the non-
DM group. The CAD group had a higher rate of β-blocker use than 
that in the non-CAD group. 
In patients with DM, metformin was more frequently prescribed 
in the CAD group than that in the non-CAD group, and an α glu-
cosidase inhibitor was more frequently prescribed in the non-CAD 
group than that in the CAD group. 
Correlations between plasma thrombospondin-1 
concentration and other variables
We examined whether TSP-1 levels correlated with any other vari-
ous parameters or medications in all patients. We found no parame-
ter or medication that correlated with TSP-1 concentration in any pa-
tient (Table 3). 
Gensini’s score was not correlated with plasma TSP-1 levels in 
CAD(+) patients (Pearson’s coefficient=-0.047, p=0.489). 
Table 2. Baseline patient medications
DM(-)CAD(-) (n=108) DM(-)CAD(+) (n=117) DM(+)CAD(-) (n=46) DM(+)CAD(+) (n=103) p
ACEi/ARB (%) 15 34 40 44 <0.001
β-blocker (%) 22 42 22 37 0.005
CCB (%) 19 15 33 21 0.081
Thiazide (%) 14 23 27 18 0.210
α-blocker (%) 0 1 2 1 0.565
Satin (%) 21 36 31 33 0.074
Metformin (%) 9 24 0.041
Sulfonylurea (%) 22 29 0.427
α-GI (%) 27 10 0.012
TZD (%) 7 3 0.369
Insulin (%) 7 9 1.000
DM(-)CAD(-): patients without DM or CAD, DM(-)CAD(+): patients without DM but with CAD, DM(+)CAD(-): patients with DM but without CAD, DM(+) 
CAD(+): patients with DM and CAD, DM: diabetes mellitus, CAD: coronary artery disease, ACEi/ARB: angiotensin converting enzyme inhibitor/angiotensin 
receptor blocker, CCB: calcium channel blocker, α-GI: α glucosidase inhibitor, TZD: thiazolinedione
Table 3. Correlation between plasma TSP-1 concentration and other param-
eters in all patients and patients with DM
All patients DM patients
Pearson correlation 
coefficient
p
Pearson correlation
coefficient
p
Age (years) -0.032 0.537 0.001 0.994
BMI (kg/m
2) -0.082 0.116 -0.068 0.412
Serum Cr (mg/dL) 0.050 0.331 0.101 0.222
TC (mg/dL)  0.029 0.581 -0.038 0.648
TG (mg/dL) -0.061 0.248 -0.146 0.076
HDL-C (mg/dL) 0.032 0.539 -0.027 0.746
LDL-C (mg/dL) 0.028 0.590 -0.007 0.936
Uric acid (mg/dL) -0.002 0.969 0.056 0.501
hs-CRP (mg/L) 0.076 0.149 -0.004 0.962
HbA1c (%) - 0.040 0.631
ACEi/ARB (%) 0.013 0.797 -0.015 0.860
β-blocker (%) -0.004 0.943 0.105 0.204
CCB (%) 0.031 0.551 0.064 0.436
Thiazide (%) -0.021 0.689 -0.031 0.707
α-blocker (%) 0.016 0.762 0.012 0.889
Statin (%) -0.064 0.220 0.093 0.262
Metformin (%) -0.015 0.857
Sulfonylurea (%) 0.085 0.305
α-GI (%) 0.002 0.977
TZD (%) -0.083 0.317
Insulin (%)  0.022 0.795
TSP-1: thrombospondin-1, DM: diabetes mellitus, BMI: body mass index, 
Serum Cr: serum creatinine, TC: total cholesterol, TG: triglyceride, HDL-C: 
high density lipoprotein-cholesterol, LDL-C: low density lipoprotein-choles-
terol, hs-CRP: high sensitivity C-reactive protein, HbA1c: glycated hemoglo-
bin level, ACEi/ARB: angiotensin converting enzyme inhibitor/angiotensin 
receptor blocker, CCB: calcium channel blocker, α-GI: α glucosidase inhibi-
tor, TZD: thiazolinedione104  Thrombospodin-1 and Coronary Artery Disease
http://dx.doi.org/10.4070/kcj.2012.42.2.100 www.e-kcj.org
Logistic regression analysis
A simple logistic regression analysis showed that CAD was sig-
nificantly correlated with gender, BMI, HDL-C, and plasma TSP-1 
levels in patients with DM (Table 4). Simple logistic regression 
analysis variables with a p<0.20 were entered into a multivariate 
logistic model. The analysis revealed that male gender and HDL-C, 
HbA1c, and plasma TSP-1 levels were independently correlated 
with the development of CAD in patients with DM (OR, 2.728; 95% 
CI, 1.035-7.187; OR. 0.936; 95% CI, 0.894-0.979; OR, 1.373; 95% 
CI, 1.037-1.817; OR, 1.003; 95% CI, 1.000-1.007, respectively). 
In non-DM patients, age, male gender, and family history were in-
dependent factors for CAD (OR, 1.043; 95% CI, 1.011-1.075; OR, 
2.212; 95% CI, 1.159-4.222; OR, 3.350; 95% CI, 1.241-9.044, re-
spectively).
Discussion
The present study is the first to show a link between human plas-
ma TSP-1 concentrations and CAD in patients with DM. We found 
that plasma TSP-1 levels were higher in DM(+) CAD(+) patients 
than those in other patients, but that plasma TSP-1 levels were not 
different between CAD and non-CAD patients in patients without 
DM. A multivariate analysis showed that a high TSP-1 level was an 
independent predictor of CAD in patients with DM.
Vascular smooth muscle cell (VSMC) migration and proliferation 
are key events in the development of atherosclerotic lesions. VSMCs 
from patients with diabetes exhibit increased proliferation, adhe-
sion, and migration. Stimulating VSMCs through increased levels of 
TSP-1 in the diabetic vessel wall may explain the enhanced prolif-
eration of VSMCs.
18)19) Two mechanisms have been suggested for 
the effect of higher plasma TSP-1 level on atherosclerosis in patients 
with DM.
8) First, dysfunction of endothelial cells (ECs) in patients 
with DM is well known
20) and TSP-1 certainly contributes to this 
dysfunction because of its antiproliferative and apoptotic effects 
on ECs.
21)22) Second, although TSP-1 in diabetic vessels may affect 
metabolism of the luminal EC monolayer and VSMCs, the large 
amounts of TSP-1 present in the adventitia ultimately results in com-
promised growth and remodeling of the vasa vasorum. Indeed, a 
previous study showed that the number of vasa vasorum cells de-
crease in the diabetic aorta and are inversely correlated with TSP-1 
expression, a potent antiangiogenic agent.
8) In blood vessels, this 
may lead to ischemic conditions in the inner layers of the vessel 
wall, and such oxygen stress could stimulate VSMC proliferation 
and initiate atherosclerotic lesions. 
Few studies of the effect of TSP-1 on CAD have been performed 
in humans. McGillicuddy et al.
23) showed that fluvastatin decreases 
TSP-1 expression and abolishes the ability of transforming growth 
factor-β1 to induce TSP-1 expression in cultured human coronary 
artery smooth muscle cells. Recent studies have linked the TSP fa-
mily, including TSP-1, to the development of atherosclerosis at the 
genetic level.
24-26)
Glucose regulates the expression of a number of vascular genes.
27) 
Table 4. Logistic regression analysis for CAD in patients with DM
Parameter
Univariate Multivariate
p  OR 95% CI p  OR 95% CI
Age (years) 0.312 1.019 0.982-1.057
Male (%) 0.005 2.835 1.375-5.847 0.042 2.728 1.035-7.187
Smoking (%) 0.150 1.784 0.811-3.923 0.947 1.035 0.379-2.822
HTN (%) 0.624 1.196 0.584-2.452
Family Hx (%) 0.527 1.541 0.404-5.885
BMI (kg/m
2) 0.033 0.885 0.790-0.990 0.189 0.912 0.794-1.047
Serum Cr (mg/dL) 0.163 2.388 0.703-8.107 0.981 1.021 0.184-5.676
TC (mg/dL) 0.053 0.992 0.985-1.000 0.741 1.002 0.991-1.012
TG (mg/dL) 0.077 0.996 0.992-1.000 0.119 0.995 0.988-1.001
HDL-C (mg/dL) <0.001 0.936 0.902-0.970 0.004 0.936 0.894-0.979
LDL-C (mg/dL) 0.979 1.000 0.992-1.008
Uric acid (mg/dL) 0.068 1.215 0.986-1.498 0.730 1.055 0.777-1.433
hs-CRP (mg/L) 0.087 1.320 0.961-1.813 0.200 1.264 0.883-1.809
HbA1c (%) 0.106 1.204 0.961-1.509 0.027 1.373 1.037-1.817
TSP-1 (ng/mL) 0.022 1.004 1.001-1.007 0.044 1.003 1.000-1.007
CAD: coronary artery disease, DM: diabetes mellitus, OR: odds ratio, CI: confidence interval, Serum Cr: serum creatinine, HTN: hypertension, Family Hx: 
family history of CAD, BMI: body mass index, TC: total cholesterol, TG: triglyceride, HDL-C: high density lipoprotein-cholesterol, LDL-C: low density lipopro-
tein-cholesterol, hs-CRP: high sensitivity C-reactive protein, HbA1c: glycated hemoglobin level, TSP-1: thrombospodin-1105 Kyu-Young Choi, et al.
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Activation of TSP-1 transcription is mediated by the glucose hex-
osamine pathway of catabolism, resulting in modulation of nuclear 
protein activity via glycosylation.
9) In the present study, the TSP-1 
level of DM(-)CAD(+) patients was not higher than that of DM(-) 
CAD(-) patients, suggesting that the release of TSP-1 is not related 
with CAD in patients without DM. We also found higher concen-
trations of human plasma TSP-1 in DM(+)CAD(+) patients com-
pared to those in the other groups (Fig. 1A). However, we found that 
TSP-1 was not correlated with HbA1c. Gensini’s score was not po-
sitively correlated with plasma TSP-1 level in patients with CAD, 
suggesting that a high TSP-1 level did not result in severe CAD. 
Some differences in medication usage were observed, but Table 
3 shows no correlation between medication use and plasma TSP-1 
levels, suggesting that the differences in TSP-1 levels do not origi-
nate from medication differences. 
A multivariate regression analysis of patients with DM showed 
that male gender, a low level of HDL-C, a high level of HbA1c, and a 
high level of plasma TSP-1 were independently and positively asso-
ciated with CAD. Male gender and a low level of HDL-C are well 
known risk factors for cardiovascular events. In prospective epide-
miological studies, the incidence of CAD is directly associated with 
the degree of hyperglycemia, as measured by HbA1c. After adjust-
ing for other risk factors, an increase of 1% in the HbA1c level is as-
sociated with an 18% increased risk for cardiovascular events.
28) We 
found that high HbA1c level was a risk factor for CAD, as previously 
reported. 
Our findings suggest that high TSP-1 plasma levels may be asso-
ciated with CAD in patients with DM. Although the physiological 
function of TSP-1 in humans is not fully understood, our cross-sec-
tional data showed a positive correlation between plasma TSP-1 and 
the incidence of CAD in patients with DM. Long-term clinical follow-
up with a larger group of patients with DM is required to confirm 
these findings. 
Study limitations
The present study had some limitations. First, we enrolled a rela-
tively small number of patients. Second, the study only included pa-
tients undergoing CAG, which may have biased the findings. Third, 
the prevalence of diabetes may have been underestimated, because 
a 75-g oral glucose tolerance test was not performed.
Conclusion
Plasma TSP-1 levels were higher in DM(+)CAD(+) patients than 
those in other patients. But, in the non-DM group, plasma TSP-1 
levels showed no difference between patients with or without CAD. 
Plasma TSP-1 level was an independent predictor for CAD in pa-
tients with DM, indicating that increased plasma TSP-1 level might 
be associated with CAD in patients with DM.
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